{
    "clinical_study": {
        "@rank": "163024", 
        "brief_summary": {
            "textblock": "This is an open-label protocol designed to provide continued access to maraviroc to only\n      those subjects who have completed previous studies of maraviroc and continue to receive\n      clinical benefit."
        }, 
        "brief_title": "An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc", 
        "completion_date": {
            "#text": "January 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Infection, Human Immunodeficiency Virus", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Evidence of a personally signed and dated informed consent document indicating that\n             the subject (or a legally acceptable representative) has been informed of all\n             pertinent aspects of the study.\n\n          -  Subject has participated in a clinical trial that evaluated maraviroc and is\n             continuing to derive clinical benefit from maraviroc treatment.\n\n          -  Subject must agree to use an acceptable method of contraception for the duration of\n             the study as outlined at the end of the inclusion criteria.\n\n          -  Subject agrees to the specified study procedures.\n\n        Exclusion Criteria:\n\n          -  Subject who is an investigational site staff member or an employee of the Sponsor\n             that is directly involved in the conduct of the trial.\n\n          -  Other severe, acute, or chronic medical or psychiatric condition or laboratory\n             abnormality that may increase the risk associated with study participation and, in\n             the judgment of the investigator, would make the subject inappropriate for entry into\n             this study.\n\n          -  Contra-indications to use of maraviroc as described in the Investigator Brochure.\n\n          -  Past documented dual/mixed or C-X-C chemokine receptor type 4 HIV tropism."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "124", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01776996", 
            "org_study_id": "116278"
        }, 
        "intervention": {
            "description": "All subjects will be on maraviroc 300 mg twice a day, unless a dose adjustment is required due to certain concomitant medications.  For those subjects in South Africa and Argentina who were previously receiving Combivir along with maraviroc in Study A4001026, Combivir will be supplied as tablets containing 150 mg lamivudine and 300 mg zidovudine.  One Combivir tablet will be taken orally twice a day.", 
            "intervention_name": "Continued Access Arm", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Expanded access, HIV, maraviroc", 
        "lastchanged_date": "October 4, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Rosario", 
                        "country": "Argentina", 
                        "state": "Santa Fe", 
                        "zip": "2000"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina", 
                        "zip": "C1264AAV"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina", 
                        "zip": "C1282AEN"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina", 
                        "zip": "1202"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1000"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium", 
                        "zip": "9000"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "B-3000"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "Lombardia", 
                        "zip": "20127"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Modena", 
                        "country": "Italy", 
                        "zip": "41124"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bydgoszcz", 
                        "country": "Poland", 
                        "zip": "85-030"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "111123"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "129110"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "N.Novgorod", 
                        "country": "Russian Federation", 
                        "zip": "603005"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint-Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "190103"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Smolensk", 
                        "country": "Russian Federation", 
                        "zip": "214006"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "196645"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Soweto", 
                        "country": "South Africa", 
                        "state": "Gauteng", 
                        "zip": "2013"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bloemfontein", 
                        "country": "South Africa", 
                        "zip": "9301"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dundee", 
                        "country": "South Africa", 
                        "zip": "3000"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gauteng", 
                        "country": "South Africa", 
                        "zip": "2047"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Port Elizabeth", 
                        "country": "South Africa", 
                        "zip": "6070"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pretoria", 
                        "country": "South Africa", 
                        "zip": "0083"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pretoria North", 
                        "country": "South Africa", 
                        "zip": "0116"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Westdene", 
                        "country": "South Africa", 
                        "zip": "2092"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bern", 
                        "country": "Switzerland", 
                        "zip": "CH-3010"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lugano", 
                        "country": "Switzerland", 
                        "zip": "6900"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zuerich", 
                        "country": "Switzerland", 
                        "zip": "8091"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Argentina", 
                "Belgium", 
                "Italy", 
                "Poland", 
                "Russian Federation", 
                "South Africa", 
                "Switzerland"
            ]
        }, 
        "official_title": "An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc", 
        "overall_official": {
            "affiliation": "ViiV Healthcare", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Argentina: Ciudad Autonma de Buenos Aires", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Provide continued access to Maraviroc to subjects who have completed previous studies of Maraviroc and continue to receive clinical benefit.", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01776996"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "ViiV Healthcare", 
        "sponsors": {
            "collaborator": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "ViiV Healthcare", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}